KaloBios Pharma edges higher following IPO

(AP)—Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.

KaloBios Pharmaceuticals Inc. says its initial public offering of 8.8 million shares priced at $8 per share. The company's stock is now trading on the Nasdaq Global Market under the ticker symbol "KBIO." In early trading the stock gain 9 cents to $8.09.

The underwriters of the offering will have the option to buy another 1.3 million shares to cover any over allotments.

In January KaloBios said it intended to sell 3.9 million shares for $12 to $14 per share.

The company is based in South San Francisco, Calif., and it is studying and treatments for and .

add to favorites email to friend print save as pdf

Related Stories

Zynga holders plan to sell up to $400M in stock

Mar 14, 2012

Zynga shareholders may sell up to $400 million of stock through a public offering, three months after the online game maker went public, to try to avoid a drop in its stock price.

Recommended for you

FDA approves new silicone breast implants

10 hours ago

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments

More news stories

More patients getting lab-grown body parts

By the time 10-year-old Sarah Murnaghan finally got a lung transplant last week, she'd been waiting for months, and her parents had sued to give her a better chance at surgery. Her cystic fibrosis was threatening ...